Menu Display

Breadcrumb

Media

U.S. News Room

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

Sun Oct 19 00:00:00 GMT-05:00 2025 NEW
DATROWAY Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Versus Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 Phase 3 Trial Download
Sun Oct 19 00:00:00 GMT-05:00 2025 NEW
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2,3 Trial Download
Sun Oct 19 00:00:00 GMT-05:00 2025 NEW
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1,2 Trial Download
Sat Oct 18 00:00:00 GMT-05:00 2025 NEW
ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial Download
Sat Oct 18 00:00:00 GMT-05:00 2025 NEW
ENHERTU Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial Download
Fri Oct 17 00:00:00 GMT-05:00 2025 NEW
DATROWAY Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial Download
Mon Oct 13 00:00:00 GMT-05:00 2025 NEW
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO Download
Tue Oct 07 00:00:00 GMT-05:00 2025 NEW
Daiichi Sankyo Joins BioLabs San Diego as Platinum Sponsor Download
Mon Oct 06 00:00:00 GMT-05:00 2025 NEW
DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 Phase 3 Trial Download
Thu Oct 02 00:00:00 GMT-05:00 2025 NEW
Daiichi Sankyo Establishes Third Research Institute in San Diego Download
Page 1 of 22
10 Items per Page
Showing 1 - 10 of 214 results.